PGC-1α, A Potential Therapeutic Target for Early Intervention in Parkinson’s Disease B Zheng, Z Liao, JJ Locascio, KA Lesniak, SS Roderick, ML Watt, ... Science translational medicine 2 (52), 52ra73-52ra73, 2010 | 743 | 2010 |
Collaborative analysis of α-synuclein gene promoter variability and Parkinson disease DM Maraganore, M De Andrade, A Elbaz, MJ Farrer, JP Ioannidis, ... Jama 296 (6), 661-670, 2006 | 568 | 2006 |
Technology in Parkinson's disease: challenges and opportunities AJ Espay, P Bonato, FB Nahab, W Maetzler, JM Dean, J Klucken, ... Movement Disorders 31 (9), 1272-1282, 2016 | 432 | 2016 |
A genomic pathway approach to a complex disease: axon guidance and Parkinson disease TG Lesnick, S Papapetropoulos, DC Mash, J Ffrench-Mullen, L Shehadeh, ... PLoS genetics 3 (6), e98, 2007 | 397 | 2007 |
Cyanobacterial neurotoxin BMAA in ALS and Alzheimer’s disease J Pablo, SA Banack, PA Cox, TE Johnson, S Papapetropoulos, ... Acta Neurologica Scandinavica 120 (4), 216-225, 2009 | 325 | 2009 |
Psychiatric comorbidities of episodic and chronic migraine DC Buse, SD Silberstein, AN Manack, S Papapetropoulos, RB Lipton Journal of neurology 260 (8), 1960-1969, 2013 | 309 | 2013 |
Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial AA Argyriou, E Chroni, A Koutras, J Ellul, S Papapetropoulos, G Katsoulas, ... Neurology 64 (1), 26-31, 2005 | 289 | 2005 |
Lrrk2 and Lewy body disease OA Ross, M Toft, AJ Whittle, JL Johnson, S Papapetropoulos, DC Mash, ... Annals of Neurology: Official Journal of the American Neurological …, 2006 | 269 | 2006 |
Peripheral nerve damage associated with administration of taxanes in patients with cancer AA Argyriou, M Koltzenburg, P Polychronopoulos, S Papapetropoulos, ... Critical reviews in oncology/hematology 66 (3), 218-228, 2008 | 267 | 2008 |
Drug repurposing from the perspective of pharmaceutical companies Y Cha, T Erez, IJ Reynolds, D Kumar, J Ross, G Koytiger, R Kusko, ... British journal of pharmacology 175 (2), 168-180, 2018 | 188 | 2018 |
Psychotic symptoms in Parkinson’s disease S Papapetropoulos, DC Mash Journal of neurology 252 (7), 753-764, 2005 | 157 | 2005 |
A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results AA Argyriou, E Chroni, A Koutras, G Iconomou, S Papapetropoulos, ... Supportive Care in Cancer 14 (11), 1134-1140, 2006 | 149 | 2006 |
Melatonin MT1 and MT2 receptor expression in Parkinson's disease N Adi, DC Mash, Y Ali, C Singer, L Shehadeh, S Papapetropoulos Medical science monitor 16 (2), BR61-BR67, 2010 | 148 | 2010 |
Preventing paclitaxel-induced peripheral neuropathy: a phase II trial of vitamin E supplementation AA Argyriou, E Chroni, A Koutras, G Iconomou, S Papapetropoulos, ... Journal of pain and symptom management 32 (3), 237-244, 2006 | 145 | 2006 |
Descriptive epidemiology of cervical dystonia G Defazio, J Jankovic, JL Giel, S Papapetropoulos Tremor and Other Hyperkinetic Movements 3, 2013 | 117 | 2013 |
Patient diaries as a clinical endpoint in Parkinson's disease clinical trials S Papapetropoulos CNS neuroscience & therapeutics 18 (5), 380-387, 2012 | 107 | 2012 |
Cortical and amygdalar Lewy body burden in Parkinson's disease patients with visual hallucinations S Papapetropoulos, DS McCorquodale, J Gonzalez, L Jean-Gilles, ... Parkinsonism & related disorders 12 (4), 253-256, 2006 | 106 | 2006 |
SRRM2, a potential blood biomarker revealing high alternative splicing in Parkinson's disease LA Shehadeh, K Yu, L Wang, A Guevara, C Singer, J Vance, ... PloS one 5 (2), e9104, 2010 | 105 | 2010 |
Post‐stroke spasticity: Predictors of early development and considerations for therapeutic intervention J Wissel, M Verrier, DM Simpson, D Charles, P Guinto, ... PM&R 7 (1), 60-67, 2015 | 96 | 2015 |
A questionnaire-based (UM-PDHQ) study of hallucinations in Parkinson's disease S Papapetropoulos, H Katzen, A Schrag, C Singer, BK Scanlon, D Nation, ... BMC neurology 8 (1), 1-8, 2008 | 95 | 2008 |